Study Contests Savings From Pay-For-Delay Bill

The Congressional Budget Office has "significantly overstated" the billions of dollars in potential savings it said would result from proposed legislation banning pay-for-delay settlements between brand-name and generic-drug companies, according to...

Already a subscriber? Click here to view full article